Oral Agents for More Than Stroke
In an exclusive report to MedPage Today, two top cardiologists discussed a new class of oral anticoagulants than turn out to do more than prevent strokes. Thomas Tu, MD, director of the cardiac catheterization lab for the Louisville Cardiology Group in Kentucky called this a "very exciting time in the field of cardiology." His colleague, Harry Büller, MD, professor of vascular medicine at the Academic Medicine Center in Amsterdam, was the principle investigator in the study of expanded clinical uses for drugs such as dabigatran, rivaroxaban, and apixaban. He maintains that although there is no approved antidote for these anticoagulants, "if we use our normal strategies to control bleeding, we will do fine."
In particular, Büller's findings showed favorable results for rivaroxaban in treating pulmonary embolism.